{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-23-000054","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.211560+00:00","generated_at":"2026-06-07T15:57:01.851994+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"FDA approves Vertex's CASGEVY gene therapy for sickle cell disease at $2.2M list price","bullets":["On Dec 8, 2023, FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.","Wholesale acquisition cost (WAC) set at $2.2 million.","CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-23-000054","json":"https://secwatch.observer/filing/0000875320-23-000054.json","markdown":"https://secwatch.observer/filing/0000875320-23-000054.md","text":"https://secwatch.observer/filing/0000875320-23-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000054/0000875320-23-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000054/vrtx-20231208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:57:01.851994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}